Entering text into the input field will update the search result below

Otsuka and Lundbeck not quite there with brexpiprazole in Alzheimer's-related agitation, new late-stage study planned

Nov. 01, 2017 7:32 AM ETOtsuka Holdings Co., Ltd. (OTSKY) StockBy: Douglas W. House, SA News Editor
  • Based on feedback from the FDA, Otsuka Pharmaceutical Co. (OTCPK:OTSKY)(OTCPK:OTSKF) and development partner H. Lundbeck A/S (OTC:HLUKF)(OTCPK:HLUYY) will conduct a third Phase 3 clinical trial assessing brexpiprazole for the treatment of agitation in Alzheimer's disease patients. The first two Phase 3s were completed earlier this year.
  • The FDA approved brexpiprazole, branded as REXULTI, in July 2015 for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder.

Recommended For You

More Trending News

About OTSKY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
OTSKY--
Otsuka Holdings Co., Ltd.